- IN₹1.09tn
- IN₹994.60bn
- IN₹281.63bn
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Indian pharma stocks fall after Trump's new drug tariffs; mostly 'sentimental', say analysts (updated)
Indian pharma stocks fall after Trump's new drug tariffs
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
India-focused pharma firms' margins to improve from GST cuts, CLSA says
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Brief: Cipla Completes Acquisition Of 20% Voting Rights In Icaltech
Publicis sues India antitrust body for denying case files in ad agencies probe
Publicis sues India antitrust body for denying case files in ad agencies probe
India's Gland Pharma posts quarterly profit rise on Cenexi recovery, Europe sales growth
Brief: Cipla Updates On USFDA Inspection At Bommasandra Facility
Street View: Line-up of key launches to drive US sales growth for India's Cipla
Brief: Cipla Preparing For Gsymbicort, And A Couple Of Inhalation Assets Launch In FY27
Brief: Cipla Q1 Consol Net Profit 12.98 Billion Rupees
Indian drugmaker Cipla beats first-quarter profit view on higher domestic demand (updated)
India's Cipla jumps on quarterly profit beat
Indian drugmaker Cipla beats first-quarter profit view
Brief: Cipla To Buy 20% Voting Rights In iCaltech Innovations
ViiV expands licence to allow generic HIV treatment production for low-income countries